The choice of first-line chronic myelogenous leukemia treatment.

Although the results were not statistically significant, a clear trend toward higher rates of MMR with 800 mg/day compared with 400 mg/day was observed, MMR rate was 49 % in the high-dose arm compared with 41 % in the standard-dose arm [ 56 ].

also in 19,460 other papers

In particular, the “Rationale and Insight for Gleevec High-Dose Therapy” (RIGHT) trial [ 52 , 53 ], testing high-dose imatinib at 800 mg/day in previously untreated CML patients, showed a trend (although not statistically significant, P = 0.07), toward improved transformation free survival (TFS) with respect to historical controls treated with standard dose in the same institution [ 53 ].

also in 53,322 other papers